Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Exclusion Criteria

• •Chemotherapy or immunotherapy within 3 weeks prior to entering study or failure to recover from adverse events due to any agents administered previously
• •Use of investigational agents within 28 days of study
• •Hematopoietic growth factors within 14 days of study
• •History of prior high dose chemotherapy with allogeneic stem cell support
• •History of prior radioimmunotherapy \</= 1 year
• •Concurrent treatment with therapeutic doses of systemic steroids
• •Pregnant or lactating female subjects
• •Concurrent, active malignancy other than lymphoma or CLL
• •Primary CNS lymphoma
• •Patients with a prior diagnosis of lymphoma active in the CNS are eligible only if CNS has been treated, and they are neurologically stable with no progressive symptoms off steroids and anti-convulsants
• •Serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of study objectives
• •Hypersensitivity to murine proteins or to any component of rituximab
• •Known positive for HIV or infectious hepatitis type C; hepatitis type B that is active and uncontrolled
• •Hypersensitivity to mannitol
• •Evidence of laboratory tumor lysis syndrome by Cairo-Bishop criteria
• •Subject with recent thromboembolic event (deep vein thrombosis or pulmonary embolism) unless clinically stable and event occurred more than 2 weeks prior to enrollment.